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able 1
revalence of nonvaccine serotypes after introduction of PCV7.
Reference Country/Region Description of Sample
Fenoll6 Greece Invasive isolates from children ≤
Brito7 Portugal Children <15 years of age with p
for SP in normal sterile body ﬂu
Cohen8 France Nasopharyngeal swabs from chi
months of age with AOM
Levy9 France Children 0–18 years of age with
meningitis
Ellis10 Buenos Aires, Argentina Patients admitted to a clinic wit
pneumococcal infection
Echániz-Aviles11 Mexico Invasive pediatric pneumococca
Delﬁno12 Uruguay Patients presenting with empye
2005–2009 (PCV7 introduced in
Mun˜oz-Almagro13 Barcelona, Spain Children with culture-proven IP
Syriopoulou14 Greece Children ≤11 years of age with I
Abate15 Mendoza, Argentina Children 0–180 months of age w
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PCV7 to PCV13: rationale for expanded-valency vaccines
Despite the widespread use of the 7-valent pneumococcal con-
jugate vaccine (PCV7) and its direct and indirect beneﬁcial impact
on the burden of pneumococcal disease worldwide, disease caused
bynonvaccine serotypes and suboptimal vaccine coverage, particu-
larly in developing nations, has somewhatmitigated the beneﬁts of
the vaccine. A recent study1 on theburdenof pneumococcal disease
among children <5 years of age indicates that, in 2000, an estimated
14.5 million episodes of serious pneumococcal disease occurred
in children 1–59 months of age. Of the estimated 155.8 million
new cases of clinical pneumonia that occur each year, the majority
(151.8 million) occur in developing countries.2 Developing coun-
tries, particularly those in sub-Saharan Africa and South-East Asia,
bear a disproportionate childhood mortality burden of pneumo-
coccal disease.2,3 In 2004, there were more than 2 million deaths
due to pneumonia among children <5 years of age in developing
countries comparedwith about 1000 deaths in this patient popula-
tion in industrialized countries, making the total number of deaths
due to pneumonia among children <5 years about 2000-fold higher
in developing countries than in industrialized countries.3
While childhood pneumococcal vaccination is nearly universal
in Europe and the United States, vaccination coverage is much
less widespread in the developing world owing to a lack of health
care resources. One of the key factors in reducing the burden
of pneumococcal disease worldwide is to improve vaccination
coverage. In a transmission-dynamic model designed to assess the
direct and indirect effects of PCV7 at various levels of vaccination
coverage, Snedecor et al.4 found that the modeled yearly incidence
of invasive pneumococcal disease (IPD; cases per 100,000 popu-
lation) in children <2 years of age, children 2–4 years of age, and
adults ≥65 years of age would decrease dramatically up to 10 years
after vaccine introduction with increasing vaccination coverage.
In an assessment of the correlation between vaccination coverage
and child hospitalization rates due to IPD in 1 state in Venezuela,5
the incidence of IPD (pneumonia, meningitis, and sepsis) in infants
and children was directly proportional to the increase in vaccine
coverage.
Another key factor in reducing the burden of pneumococ-
cal disease is to expand coverage to include all or most of the
serotypes that cause pneumococcal disease. In most countries
that have implemented PCV7 vaccination, disease caused by
vaccine serotypes has decreased. However, nonvaccine serotypes
have emerged as major causes of pneumococcal disease in the
post-PCV7 era (Table 1),6–15 underscoring the need for expanded
Trends in Nonvaccine Serotypes
14 years of age Increase in 1, 19A, 7F; decrease in 6A
ositive culture
id
Increase in 1, 19A
ldren 6–24 Increase in nonvaccine serotypes from 26.5% to 59.4%;
increase in 19A; prevalence of 6A: stable
bacterial Most prevalent: 7F, 15B/C, 19A
h Most prevalent: 1, 5
l isolates Increase in 19F
mas,
2008)
Decrease in 1, 5
D Most prevalent: 19A, 1, 19F, 7F
PD or AOM Most prevalent in IPD: 7F, 9A, 3; most prevalent in AOM:
19A, 19F, 6A
ith IPD Most prevalent in children <2 years of age: 14, 5; most
prevalent in children <5 years of age: 1
cute otitis media; IPD= invasive pneumococcal disease.
Highlights of the 6th World Congress of the WSPID / International Journal of Infectious Diseases 14S (2010) e3–e10 e7
Table 2
Estimates of serotype coverage with PCV7, PCV10, and PCV13.
Reference Country/Region Description of Sample PCV7 PCV10 PCV13
Murad22 Bandung, Indonesia Children 2–59 months of age with nonsevere
pneumonia attending a primary health center
40% 41% 48%
Mendez23 Panama Nasopharyngeal samples of 397 healthy children <5
years of age attending day care centers
56.5% 56.5% 70.0%
Bolãnos24 Panama IPD isolates from children <5 years of age 57% 70% 90%
Echániz-Aviles11 Mexico Invasive pneumococcal pediatric isolates 62.7% 68% 76.8%
Capeding25 Philippines SP isolates from 9 children 28 days to 60 months of age 75.0% – 87.5%
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RCV7=7-valent pneumococcal conjugate vaccine; PCV10=10-valent pneumococca
neumococcal disease; SP= Streptococcus pneumoniae.
erotype coverage. The 13-valent pneumococcal conjugate vaccine
PCV13) provides coverage against 6 additional pneumococ-
al serotypes—1, 3, 5, 6A, 7F, and 19A—that are not covered
y PCV7.
Serotypes 1 and 5—important causes of pneumococcal disease
orldwide, particularly in children >2 years of age—can cause
pidemic disease. Serotype 3 is a relatively frequent cause of IPD
nd otitis media, and it is associated with pneumonia, especially
omplicated (necrotizing) pneumonia and empyemas. Serotype
A remains a frequent cause of IPD and is often antibiotic resis-
ant, although there appears to be partial cross-protection from
erotype 6B in PCV7. Serotype 7F is an important cause of IPD
orldwide, and there are reports of increased case-fatality rates
rom this serotype. Serotype 19A is an important cause of IPD,
neumonia, and acute otitis media, both in countries where PCV7
s used and in countries where PCV7 has not been incorporated
nto the national immunization plan. Antibodies to 19F in PCV7 do
ot appear to induce cross-protection against 19A.
In Chile, serotypes 1, 5, 6A, 7F, 14, and 19A were the most
ommon serotypes found in isolates from children 0 months to 14
ears of age with IPD requiring hospitalization.16 Serotypes 1, 3, 5,
F, and 14 were among the most frequent serotypes observed in
hildren <18 years of age with parapneumonic empyema admitted
o hospitals in Spain17 and in pneumococcal pneumonia isolates
rom Uruguayan children.18 The prevalence of serotypes 1, 7F,
nd 19A in invasive isolates from children and adults6,19 appears
o have increased from the pre- to the post-PCV7 era, and the
usceptibility of serotype 19A to penicillin has decreased during
hat same period.20 Table 1 lists key data reported at the 6th World
ongress of the World Society for Pediatric Infectious Diseases
hat suggest an increase in disease caused by non-PCV7 vaccine
erotypes.
The incorporationof PCV13 into immunizationplans is expected
o expand serotype coverage and to make a measurable impact
n the burden of pneumococcal disease. Serotype prevalence data
rom 19 Latin American countries suggest that overall serotype
overage with PCV13 will be 86.3% in children <5 years of age.21
stimates of coverage for isolates from meningitis and pneumonia
ases are 95.4% and 90.3%, respectively.21 Similar serotype preva-
ence data from Indonesia, Panama, Mexico, and Greece suggest
hat PCV13 will improve serotype coverage compared with PCV7
r 10-valent pneumococcal conjugate vaccine (Table 2).11,22–25 An
nalysis by Dinleyici and Yargic26 indicates that serotype coverage
y PCV13 has greater potential to protect against pneumococcal
iseases and that itmay cover potential IPD-causing pneumococcal
erotypes throughout the world.eferences
1. O’Brien KL, Wolfson LJ, Watt JP, et al; Hib and Pneumococcal Global Burden of
Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in
children younger than 5 years: global estimates. Lancet 2009;374:893–902.ugate vaccine; PCV13=13-valent pneumococcal conjugate vaccine; IPD= invasive
2. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemi-
ology and etiology of childhood pneumonia. Bull World Health Organ
2008;86:408–16.
3. UNICEF/WHO. Pneumonia: the forgotten killer of children. New York, NY:
UNICEF; Geneva, Switzerland: WHO; September 2006.
4. Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF. Transmission-
dynamic model to capture the indirect effects of infant vaccination with
Prevnar (7-valent pneumococcal conjugate vaccine [PCV7]) in older popula-
tions. Vaccine 2009;27:4694–703.
5. Rísquez Parra FA, Echezuria Marval LR, Franco Soto JV. Preliminary assessment
of heptavalent pneumococcal conjugate vaccine effectiveness in hospitalized
children with invasive pneumoccocal diseases, Estado Táchira, Venezuela,
2006–2008. Presented at: the 6th World Congress of the World Society for
Pediatric Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina.
Abstract 397.
6. Fenoll A, GimenezMJ, ViciosoMD, et al. Trends of the tenmost prevalent pneu-
mococcal serotypes among invasive isolates fromchildren in the last 12years in
Spain. Presented at: the 6th World Congress of the World Society for Pediatric
Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina. Abstract
262.
7. Brito MJ. Invasive pneumococcal disease (IPD) in children in Portugal, prospec-
tive study (2006–2008). Presented at: the 6th World Congress of the World
Society for Pediatric InfectiousDiseases; November 19–22, 2009; Buenos Aires,
Argentina. Abstract 712.
8. Cohen R, Levy C, Bonnet E, et al. Does pneumococcal 7-valent conju-
gate vaccine continue to change nasopharyngeal carriage of S. pneumoniae?
Presented at: the 6th World Congress of the World Society for Pedi-
atric Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina.
Abstract 296.
9. Levy C, Varon E, Bingen E, et al. Effect of 7-valent pneumococcal con-
jugate vaccine (PCV7) on pneumococcal meningitis in French children.
Presented at: the 6th World Congress of the World Society for Pedi-
atric Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina.
Abstract 298.
10. Ellis A, Fossati S, Efron AM, et al. Epidemiological report of invasive pneumo-
coccal disease in a private clinic of Buenos Aires. Presented at: the 6th World
Congress of the World Society for Pediatric Infectious Diseases; November
19–22, 2009; Buenos Aires, Argentina. Abstract 700.
11. Echániz-Aviles G, Carnalla-Barajas MN, Soto-Noguerón A, et al. Serotypes and
antimicrobial susceptibility of invasive pneumococcal pediatric isolates in
Mexico (1994–2008). Presented at: the 6th World Congress of the World Soci-
ety for Pediatric Infectious Diseases; November 19–22, 2009; Buenos Aires,
Argentina. Abstract 1094.
12. Delﬁno M, Más M, Barrios P, et al. 7 valent pneumococcal conjugate vaccine
mass vaccination. Empyema in children before and during the year of interven-
tion. Uruguay. Presented at: the 6th World Congress of the World Society for
Pediatric Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina.
Abstract 517.
13. Mun˜oz-Almagro C, Esteva C, Hernandez S, et al. Molecular characterization
and serotypes of invasive pneumococcal disease among children in Barcelona
(2007-2008). Presented at: the 6th World Congress of the World Society for
Pediatric Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina.
Abstract 439.
14. SyriopoulouV, Syrogiannopoulos GA, Koutouzis E, et al. Paediatric pneumococ-
cal serotype epidemiology after the introduction of the heptavalent conjugated
vaccine in Greece: an interim analysis. Presented at: the 6th World Congress
of the World Society for Pediatric Infectious Diseases; November 19–22, 2009;
Buenos Aires, Argentina. Abstract 261.
15. Abate H, Falaschi A, Balbi L, Garcia B, Rosaenz A. Invasive pneu-
mococcal disease (IPD) among children in Mendoza. Argentina. Pre-
sented at: the 6th World Congress of the World Society for Pediatric
Infectious Diseases; November 19–22, 2009; Buenos Aires, Argentina.
Abstract 965.
16. Lagos R,Mun˜ozA, SanMartinO, et al. Age- and serotype-speciﬁc pediatric inva-
sive pneumococcal disease: insights from systematic surveillance in Santiago,
Chile, 1994–2007. J Infect Dis 2008;198:1809–17.
17. Obando I, Mun˜oz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic
empyema, Spain. Emerg Infect Dis 2008;14:1390–7.
e ternational Journal of Infectious Diseases 14S (2010) e3–e10
d
P
s
2
I
i
b
o
t
s
i
s
6
c
o
c
i
t
r
d
b
s
b
f
m
a
c
Table 1
Standard pediatric vaccines compatible
with PCV13.4–8
Diphtheria
Tetanus
Acellular or whole cell pertussis
Haemophilus inﬂuenzae type b
Inactivated poliomyelitis
Hepatitis B
Meningococcal serogroup C
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CV13: proven efﬁcacy and safety
This discussion is based on a presentation given at a satellite
ymposium held in Buenos Aires, Argentina, on November 20,
009, at the 6th World Congress of the World Society for Pediatric
nfectious Diseases.
Second-generation pneumococcal conjugate vaccines (PCVs),
ncluding 10-valent PCV and 13-valent PCV (PCV13), have recently
een licensed in multiple countries worldwide. PCV13 is an
ligosaccharide/polysaccharide capsular antigen conjugated with
he nontoxic mutant protein CRM197 of diphtheria toxoid, the
ame carrier protein used in the 7-valent vaccine (PCV7).
In addition to the 7 Streptococcus pneumoniae serotypes covered
n PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13 also includes
erotypes 1, 3, 5, 6A, 7F, and 19A. The inclusion of serotypes
A and 19A in PCV13 will provide additional direct pediatric
overage, and serotypes 1, 3, 5, and 7F will provide additional
titis media coverage. Coverage of all of these serotypes will
ollectively provide generally improved global coverage against
nvasive pneumococcal disease (IPD).
Studies conducted in Italy1 and Spain2 have demonstrated
hat the immunogenicity of PCV13 in a 2+1 schedule is compa-
able to that of PCV7. PCV7 administered in a 2+1 schedule has
ocumented efﬁcacy against IPD.3 Because PCV13 is designed to
e interchangeable with PCV7 at any point in the immunization
chedule, countries that are using PCV7 in the 2+1 schedule should
e able to transition directly to PCV13. Furthermore, PCV13 was
ound to be noninferior to PCV7 when given concomitantly with
ost of the standard pediatric vaccines (Table 1), and it did not
dversely affect the safety and/or immune responses of any of the
oadministered vaccines.4–8Varicella
PCV13=13-valent pneumococcal con-
jugate vaccine.
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Preventing pneumococcal disease in adults
This discussion is based on a presentation given at a satellite
symposium held in Buenos Aires, Argentina, on November 20,
2009, at the 6th World Congress of the World Society for Pediatric
Infectious Diseases.
Pneumococcal infection accounts for about 500,000 cases of
pneumonia each year in the United States and is associated with
considerable morbidity and mortality.1 Pneumonia symptoms
(i.e., fever, myalgia, dyspnea, cough, and fatigue) tend to persist,
with median times to resolution ranging from 3 days for fever to
14 days for cough and fatigue; 35% of patients have ≥1 unresolved
symptom at day 28.2 The 30-day mortality rate among patients
with pneumococcal pneumonia admitted to the intensive care
unit remains high compared with that of patients admitted to the
general ward (23% vs 4%, respectively; P<0.001).3The 23-valent pneumococcal polysaccharide vaccines (PPSVs)
currently available were licensed in 1983, replacing the earlier
14-valent formulation that was licensed in 1977.1 The Centers for
Disease Control and Prevention Advisory Committee on Immu-
